“Biopharmaceutical Excipients Market Report is set to have rapid growth due Presence of diversified suppliers and strong research funding in chemicals division at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Biopharmaceutical Excipients Market Forecast 2019-2029: By Product (Solubilizers & Surfactants/Emulsifiers, Specialty Excipients, Polyols, Carbohydrates), By Region, And Segment Forecasts.

The global Biopharmaceutical Excipients market is poised for rapid growth between 2019 and 2029. Factors such as the growing pharmaceutical industry combined with advances in functional excipients, the growing adoption of orphan drugs and the increasing uptake of biopharmaceuticals are driving the market for pharmaceutical excipients.

Some recent advancements include:

  • On December 2018, Roquette Feres (France) signed an agreement with Thermo Fisher Scientific (USA), which gives Thermo Fisher the right to distribute Roquette's product portfolio in the United States and Canada.
  • On January 2019, Croda International (United Kingdom) acquired Brenntag Biosector (Denmark) for its portfolio of vaccine adjuvants that would complement Croda's portfolio of pharmaceutical excipients.
  • On April 2019, Colorcon, Inc. (United States) signed an agreement with DuPont Nutrition and Biosciences (United States) to improve the current portfolio of CR Alliance products.
  • Onn February 2019, Associated British Foods plc (United Kingdom) signed an agreement with Indchem International (India) on the basis of which Indchem will distribute the functional lipid excipient product line of the Associated British Food on the Indian market.

Leading companies featured in the report include ABITEC Corp.; Signet Chemical Corporation Pvt. Ltd.; Roquette; Sigachi Industries Pvt. Ltd.; Meggle AG; Colorcon, Inc.; DFE Pharma; Clariant; IMCD; SPI Pharma; Pharmonix Biological Pvt. Ltd.; Spectrum Chemical Manufacturing Corp., and BASF SE

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever